-
Mashup Score: 0Facilitating End-of-Life Care for Patients With Breast Cancer - 15 day(s) ago
Oncology nurses and APPs provide support and can help to facilitate conversations with patients and families during end-of-life care.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1
Restaging cancer can be an unfamiliar space, but with more experience, APPs can rely less on MDs for guidance in such cases.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
❓ How can oncology APPs address restaging of cancer with patients? 🙋♀️ Watch the full video with Jamie Carroll, APRN, CNP, MSN: https://t.co/wkeFoojfqJ #oncologyNP #oncologyPA #oncologyAPP #cancercare https://t.co/QruA2L5Sq9
-
-
Mashup Score: 1
Cema-cel was associated with largely durable CRs in patients with CD19 CAR T-cell therapy-naïve relapsed/refractory LBCL.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
🩺 How did patients with #LBCL respond to cema-cel in early findings? 📲 Read about results of the phase 1 ALPHA and ALPHA2 trials below. #oncology #lymphoma #cancerresearch https://t.co/1aSg2wPihA
-
-
Mashup Score: 0
While ambient particle levels differed by HEPA filter status, Splashblocker significantly reduced particles emitted from toilet plume aerosols regardless.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
🚻 How can oncology nurses and APPs protect themselves from toilet plume aeresols when flushing patient excretion? 🔍 Read about how a reusable toilet seat cover can lessen the range of toxins. #oncologynurse #oncology #nursing https://t.co/9QYwKaSVsm
-
-
Mashup Score: 1Approvals in Cancer Care Call for Multidisciplinary Cooperation - 18 day(s) ago
Working with multidisciplinary teams and educating patients are key to treating patients with cancer while navigating newly approved treatments.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
💡 Kayla Freeman, DNP, APRN, FNP-C, explained that patient education and interdisciplinary collaboration can help patients remain on newly approved therapies. 📹 Watch here: https://t.co/HrHJHCBc8n
-
-
Mashup Score: 0
Working with interdisciplinary teams and nurse navigators to coordinate care across specialties is a facet of oncology nursing that may be overlooked, says an expert.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
🏥 Watch Jessie Desir, PhD, RN, AMB-BC, OCN, discuss the importance of working with interdisciplinary teams and nurse navigators. 🎥 Full video here: https://t.co/1dxchKS8hi #cancercare #oncology #nursenavigator #oncologynurse https://t.co/7GVdhnpDgU
-
-
Mashup Score: 0
Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
📲 Could a medication-tracking mobile app affect oral medication adherence in patients with cancer? 🧑💻 Read about patient satisfaction and adherence with the Medisafe app here: https://t.co/lhQ7icoqoi #cancercare #oncology #oncologynurse #breastcancer
-
-
Mashup Score: 0
Real-world data show that older adults with lenalidomide-refractory MM have poor survival outcomes after 1 to 3 lines of therapy.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
Real-world data show a gap in treatment for older patients with lenalidomide-refractory multiple myeloma who have recieved 1 or more prior lines of therapy. Read more here: https://t.co/Z7FcHODs1q #multiplemyeloma #oncology #oncologynurse
-
-
Mashup Score: 0
Clinical response rates were higher in patients with phlebotomy-dependent polycythemia vera who received rusfertide than in those who received placebo.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
When added to SOC, rusfertide achieved higher clinical response rates vs placebo in patients with phlebotomy-dependent polycythemia vera. Read the full story here: https://t.co/PSqftFmnAD
-
-
Mashup Score: 0
The FDA has granted PYX-201 fast track designation for treatment of recurrent or metastatic HNSCC after progression post-chemoimmunotherapy.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
The FDA granted PYX-201 fast track designation for treatment of recurrent or metastatic HNSCC after progression post-chemoimmunotherapy. Read about it here: https://t.co/nvULgj53A1
-
🫂 La-Urshalar Brock, MSN, CNM, FNP-BC, shared her insights on facilitating supportive care at the end of life for patients with cancer. 🎥 Watch the full video: https://t.co/LKPPqlcb6Q #supportivecare #compassionatecare #breastcancer #cancercare https://t.co/5Nrme1jL2k